Want to see SE:NXTCL full AI Analyst Report?
Top Page
NextCell Pharma AB
(NXTCL)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr1.00
▲(8.70% Upside)
Action:Reiterated
Date:09/10/26
Overall score reflects very weak financial performance driven by persistent losses and heavy cash burn, partially offset by the absence of debt. Technicals are neutral with price above key moving averages but muted momentum (slightly negative MACD and neutral RSI). Valuation is difficult to support because earnings are negative (negative P/E) and no dividend yield is available.
Positive Factors
Debt-free balance sheet
The absence of reported debt reduces refinancing pressure and interest obligations, giving NextCell greater financial flexibility than a similarly loss-making company with leverage. This can help preserve strategic options while the business funds clinical development and commercialization efforts.
Negative Factors
Persistent unprofitability
Deeply negative gross and net margins show that current revenue does not cover the cost structure or development investment. Without material improvement in economics, continued losses can constrain reinvestment capacity and make the path to sustainable profitability highly uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of reported debt reduces refinancing pressure and interest obligations, giving NextCell greater financial flexibility than a similarly loss-making company with leverage. This can help preserve strategic options while the business funds clinical development and commercialization efforts.
Read all positive factors
NextCell Pharma AB (NXTCL) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr127.91M
Dividend YieldN/A
Average Volume (3M)375.69K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue Growth-4.02%
EPS Growth35.86%
CountrySE
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding126,392,960
10 Day Avg. Volume227,002
30 Day Avg. Volume375,685
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.36
Price to Sales (P/S)8.24
P/FCF Ratio-2.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)kr254.00M
NextCell Pharma AB Business Overview & Revenue Model
Company Description
NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an inves...
NextCell Pharma AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.09M | 10.94M | 10.66M | 10.11M | 5.59M | 3.91M |
| Gross Profit | -45.17M | -35.87M | -4.56M | -884.83K | -22.26M | -14.53M |
| EBITDA | -42.47M | -32.63M | -40.99M | -39.36M | -34.10M | -24.21M |
| Net Income | -44.48M | -35.14M | -41.96M | -39.81M | -34.08M | -24.56M |
Balance Sheet | ||||||
| Total Assets | 63.90M | 76.73M | 81.29M | 88.83M | 124.66M | 155.63M |
| Cash, Cash Equivalents and Short-Term Investments | 21.09M | 38.72M | 46.79M | 50.03M | 97.12M | 139.17M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 16.83M | 10.34M | 13.69M | 13.10M | 9.12M | 5.53M |
| Stockholders Equity | 47.07M | 66.39M | 67.60M | 75.73M | 115.54M | 150.09M |
Cash Flow | ||||||
| Free Cash Flow | -57.71M | -43.05M | -37.86M | -47.92M | -40.90M | -26.30M |
| Operating Cash Flow | -52.97M | -38.86M | -37.78M | -43.83M | -33.31M | -25.58M |
| Investing Cash Flow | -5.00M | -4.24M | -83.51K | -4.10M | -9.37M | -5.84M |
| Financing Cash Flow | 84.36M | 35.03M | 34.63M | 835.66K | 608.17K | 148.63M |
NextCell Pharma AB Technical Analysis
Negative
0.92
Price Trends
1.07
Negative
1.08
Negative
1.13
Negative
Market Momentum
>-0.01
Positive
43.49
Neutral
21.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NXTCL, the sentiment is Negative. The current price of 0.92 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.07, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.49 is Neutral, neither overbought nor oversold. The STOCH value of 21.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NXTCL.
NextCell Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr41.62M | 14.48 | 21.37% | ― | 837.37% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr127.91M | -2.66 | -81.23% | ― | -4.02% | 35.86% | |
48 Neutral | kr182.52M | -7.68 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr429.45M | -3.64 | -18.05% | ― | ― | 15.97% | |
42 Neutral | kr148.14M | -2.77 | 245.07% | ― | -38.46% | 9.02% | |
41 Neutral | kr81.08M | -1.93 | ― | ― | ― | 13.53% |
* Healthcare Sector Average
SE:NXTCL
NextCell Pharma AB
1.02
0.05
5.49%
SE:XINT
Xintela AB
0.16
-0.22
-57.81%
SE:ELIC
Elicera Therapeutics AB
2.72
-2.01
-42.54%
SE:IMMU
Immunicum AB
6.51
-0.19
-2.84%
SE:FLUI
Fluicell AB
29.60
11.00
59.14%
SE:ANNX
Annexin Pharmaceuticals AB
9.02
-19.15
-67.98%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.